Monitor for the effective date of this S-3 and subsequent selling by the large holders (Bleichroeder LP at 68.5% pre-offering, Armistice Capital at 38.0%). Any open market sales by these holders will create severe downward pressure on the stock. The October 2026 Common Warrants are not exercisable until April 2027, but the pre-funded warrants and outstanding shares can be resold immediately upon effectiveness.
Drug in focus
CRIS drug pipeline →emavusertib
◆ Mixed Named in this S-3- Impact
- Phase
- Phase 2 (registrational-intent in PCNSL)
- Time to market
- Uncertain; the registrational PCNSL study is still enrolling with full enrollment targeted within 12-18 months from March 2026. If data are positive and an NDA follows, potential approval would be at least 2-3 years out, assuming sufficient capital to complete the trials.
- Next catalyst
- None dated
What to watchThe next major catalyst is a topline data readout from the registrational TakeAim Lymphoma study in PCNSL, which management targeted to fully enroll within 12-18 months from March 2026 (so late 2027 at the earliest). No specific readout date has been announced. In the near term, watch for the shareholder vote on the proposed reverse stock split, which the company needs to maintain Nasdaq listing, and for any further financing rounds given the cash burn (Q3 2026 net loss of $8.12M).
Price Chart
How similar events traded
Executive Summary
Curis filed an S-3 registration statement to register the resale of up to 33,333,360 shares of common stock by selling stockholders, consisting of 2,574,517 outstanding shares, 14,092,163 shares issuable upon exercise of pre-funded warrants, and 16,666,680 shares issuable upon exercise of common warrants, all issued in an October 2026 private placement. The company will not receive any proceeds from the resale, only from any cash exercise of the warrants. This filing, combined with the company's $4M market cap, no revenue, net losses, and a going concern warning, signals severe financial distress and massive potential dilution.
Key Financial Metrics
Key Facts
- S-3 registers resale of up to 33,333,360 shares by selling stockholders from October 2026 private placement
- Shares consist of 2,574,517 common shares, 14,092,163 pre-funded warrant shares, and 16,666,680 common warrant shares
- October 2026 Common Warrants have exercise price of $0.60 per share, exercisable from April 19, 2027 to April 19, 2032
- October 2026 Pre-Funded Warrants have exercise price of $0.01 per share, exercisable immediately
- Company will not receive proceeds from resale, only from any cash exercise of warrants
- Market cap is $4M; 33.3M shares represent approximately 500% of the 6.7M shares outstanding as of October 20, 2026
- Company has no revenue following 2025 sale of Erivedge royalties, reported Q3 2026 net loss of $8.1M
- Auditor's report includes going concern explanatory paragraph
- This is the 8th offering/registration filing in the last 24 months
Financial Impact
Potential dilution of up to 500% of current shares outstanding; maximum aggregate offering price of $20.3M based on filing fee calculation, which is ~5x the company's $4M market cap
Risk Factors
- Massive dilution: 33.3M shares registered vs 6.7M shares outstanding, representing ~500% potential dilution
- Going concern risk highlighted in auditor's report and company's forward-looking statements
- No revenue and continued operating losses with cash runway only into Q1 2027
- Selling stockholders include entities that may be deemed underwriters, potentially accelerating share sales
- Stock price of $0.5718 is below the $0.60 exercise price of the common warrants, making cash exercise unlikely
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001104659-26-127083 |
| Document: tm2629549d1_ex-filingfees.htm | 0001104659-26-127083 |
| Document: tm2629549d1_ex5-1.htm | 0001104659-26-127083 |
| Document: tm2629549d1_ex23-2.htm | 0001104659-26-127083 |
| Document: 0001104659-26-127083-index-headers.html | 0001104659-26-127083 |
| Document: 0001104659-26-127083-index.html | 0001104659-26-127083 |
| Document: 0001104659-26-127083.txt | 0001104659-26-127083 |
Track record
18 reports on CRIS
7 of 9 bullish or bearish reports moved the stock their way by T+1. Best: +82.45% at T+60 after the May 22, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.4200 Now $0.4400 +4.76% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.6000 Now $0.4400 −26.67% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5010 Now $0.4400 −12.18% settles Nov 17
- Nov 13, 20263d ago S-3 Bearish 7/10 Viewing Entry $0.6000 Now $0.4400 +26.67% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $0.4450 Now $0.4400 −1.12% settles Nov 17
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $0.4450 to $0.4358 Now $0.4400 +1.12% ▲ +2.07% +0.16% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $0.6530 to $0.5915 Now $0.4400 −32.62% ▼ −9.42% −10.74% vs SPY
- Nov 6, 202610d ago 8-K Bearish 7/10 Entry $0.6976 to $0.6530 Now $0.4400 +36.93% ▲ +6.39% +6.03% vs SPY
- Nov 2, 202614d ago DEF 14A Neutral 4/10 Entry $0.6610 to $0.7139 Now $0.4400 −33.43% ▲ +8.00% +7.70% vs SPY
- Oct 19, 202628d ago 8-K Bearish 6/10 Entry $0.3996 to $0.3920 Now $0.4400 −10.11% ▲ +1.90% +2.43% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers